Peripheral Blasts at Apheresis as a Risk Factor for Survival following Tisagenlecleucel in Children and Young Adults.
Lower blast counts before CAR-T cell harvesting predict better outcomes in children with relapsed leukemia, guiding intensity of pre-treatment therapies.
This study identifies peripheral blast count at leukapheresis as a significant predictor of poor outcomes following tisagenlecleucel infusion in relapsed/refractory pediatric B-ALL, providing actionable guidance for patient selection and bridging therapy strategy. The finding supports systematic blast reduction before apheresis to improve CAR-T cell product quality and clinical outcomes.
What the study was
- Study design
- Retrospective cohort study
- Population
- Pediatric and young adult relapsed/refractory B-ALL patients
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Blood advances
Why it surfaced
Clinically actionable predictor for CAR-T outcome in pediatric B-ALL; identifies a modifiable pre-treatment factor with direct implications for apheresis timing and bridging therapy.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.